{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:49:45Z","timestamp":1790700585695,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011773","name":"Bourgogne-Franche-Comte Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.canrad.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T15:14:56Z","timestamp":1630163696000},"page":"533-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effet abscopal\u00a0: mythe ou r\u00e9alit\u00e9\u00a0?"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-9421","authenticated-orcid":false,"given":"C.","family":"Mirjolet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-4975","authenticated-orcid":false,"given":"G.","family":"Truc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2021.07.002_bib0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0140","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canrad.2021.07.002_bib0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.canrad.2021.07.002_bib0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0155","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.canrad.2021.07.002_bib0160","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers11060860","article-title":"The 6th R of radiobiology: reactivation of anti-tumor immune response","volume":"11","author":"Boustani","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2021.07.002_bib0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","article-title":"Barriers to radiation-induced in situ tumor vaccination","volume":"8","author":"Wennerberg","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0170","doi-asserted-by":"crossref","first-page":"20200042","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67\u00a0years later: from a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0175","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4\u00a0blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2021.07.002_bib0180","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.07.002_bib0185","first-page":"5","article-title":"Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review","volume":"9","author":"Chicas-Sett","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0190","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1\u00a0regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.canrad.2021.07.002_bib0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1\u00a0and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2021.07.002_bib0200","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of radiotherapy and immunotherapy for treatment of oligometastases","volume":"20","author":"Pitroda","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2021.07.002_bib0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-017-0013-8","article-title":"Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma","volume":"2","author":"Reuben","year":"2017","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.canrad.2021.07.002_bib0220","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13014-019-1227-y","article-title":"Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects","volume":"14","author":"Tubin","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0230","first-page":"30","article-title":"Spatially fractionated radiation therapy: history, present and the future","volume":"20","author":"Yan","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3\u00a0phase 1\/2\u00a0trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.07.002_bib0240","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2020.08.023","article-title":"Radiation therapy and the in situ vaccination approach","volume":"108","author":"Golden","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.07.002_bib0245","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.07.002_bib0250","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1\u00a0and CTLA-4\u00a0immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.07.002_bib0255","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.07.002_bib0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001\u00a0phase 1\u00a0trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:34:11Z","timestamp":1761136451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321821001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":26,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1278321821001542"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2021.07.002","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effet abscopal\u00a0: mythe ou r\u00e9alit\u00e9\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}